MX356050B - Composicion farmaceutica acuosa con estabilidad mejorada. - Google Patents

Composicion farmaceutica acuosa con estabilidad mejorada.

Info

Publication number
MX356050B
MX356050B MX2014009573A MX2014009573A MX356050B MX 356050 B MX356050 B MX 356050B MX 2014009573 A MX2014009573 A MX 2014009573A MX 2014009573 A MX2014009573 A MX 2014009573A MX 356050 B MX356050 B MX 356050B
Authority
MX
Mexico
Prior art keywords
composition
pharmaceutical composition
aqueous pharmaceutical
enhanced stability
aqueous
Prior art date
Application number
MX2014009573A
Other languages
English (en)
Other versions
MX2014009573A (es
Inventor
L Meadows David
W Davis James
Chiou Jang-Shing
Allen Ketelson Howard
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2014009573A publication Critical patent/MX2014009573A/es
Publication of MX356050B publication Critical patent/MX356050B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención es una composición farmacéutica acuosa que incluye un agente terapéutico ionizado, un componente iónico y goma guar. La goma guar está presente en la composición a una concentración suficiente para limitar interacciones entre el agente terapéutico ionizado y el componente iónico altera de esta manera la estabilidad de la composición. Preferiblemente la composición está en o cerca del pH fisiológico. Se ha encontrado que la composición farmacéutica acuosa es particularmente útil como una composición oftálmica, ática o nasal acuosa. La composición farmacéutica, debido a su característica, es particularmente adecuada como una composición oftálmica.
MX2014009573A 2012-02-10 2013-02-08 Composicion farmaceutica acuosa con estabilidad mejorada. MX356050B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597416P 2012-02-10 2012-02-10
PCT/US2013/025376 WO2013119974A1 (en) 2012-02-10 2013-02-08 Aqueous pharmaceutical composition with enhanced stability

Publications (2)

Publication Number Publication Date
MX2014009573A MX2014009573A (es) 2015-04-08
MX356050B true MX356050B (es) 2018-05-11

Family

ID=47750831

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009573A MX356050B (es) 2012-02-10 2013-02-08 Composicion farmaceutica acuosa con estabilidad mejorada.

Country Status (12)

Country Link
US (2) US20130210812A1 (es)
EP (1) EP2811979B1 (es)
JP (1) JP6180443B2 (es)
KR (1) KR102047954B1 (es)
CN (1) CN104168885A (es)
AU (1) AU2013216847B2 (es)
BR (1) BR112014019742A8 (es)
CA (1) CA2864165A1 (es)
MX (1) MX356050B (es)
RU (1) RU2014136715A (es)
TW (1) TW201336527A (es)
WO (1) WO2013119974A1 (es)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE69834154T2 (de) 1997-07-01 2007-01-25 Pfizer Products Inc., Groton Verfahren zur Herstellung von einem Cyclodextrin
US6403609B1 (en) * 1997-07-29 2002-06-11 Alcon Manufacturing, Ltd. Ophthalmic compositions containing galactomannan polymers and borate
WO2001054687A1 (en) * 2000-01-25 2001-08-02 Alcon Universal Ltd. Ophthalmic anti-allergy compositions suitable for use with contact lenses
AU2003213210A1 (en) * 2002-02-22 2003-09-09 Pharmacia Corporation Ophthalmic formulation with gum system
WO2004069157A2 (en) * 2003-01-17 2004-08-19 Ophthalmic Research Associates, Inc. Combinational use of long-acting and short-acting anti-histamines for ocular allergies
WO2008015695A2 (en) * 2006-05-15 2008-02-07 Sun Pharmaceutical Industries Limited Inclusion complex of olopatadine and cyclodextrin
TWI434926B (zh) 2006-12-11 2014-04-21 Alcon Res Ltd 眼用組成物中聚氧化乙烯-聚氧化丁烯（ｐｅｏ-ｐｂｏ）嵌段共聚物之使用
DK2114367T3 (en) * 2007-02-07 2015-12-07 Novartis Ag Olopatadine formulations for topical nasal administration
WO2008100807A2 (en) * 2007-02-09 2008-08-21 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of three polymers
TW200904485A (en) * 2007-05-18 2009-02-01 Alcon Res Ltd Phospholipid compositions for contact lens care and preservation of pharmaceutical compositions
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
BRPI1008654A2 (pt) 2009-02-05 2016-03-08 Alcon Res Ltd processo para purificação de guar
TWI478730B (zh) * 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
HUE025838T2 (en) * 2009-12-03 2016-04-28 Alcon Res Ltd Nanoparticulate suspensions containing carboxyvinyl polymer
AU2011248129B2 (en) * 2010-05-05 2014-10-09 Alcon Inc. Stabilized ophthalmic galactomannan formulations
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
TWI544922B (zh) * 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物

Also Published As

Publication number Publication date
BR112014019742A8 (pt) 2017-07-11
KR20140120932A (ko) 2014-10-14
RU2014136715A (ru) 2016-03-27
US20130210812A1 (en) 2013-08-15
EP2811979A1 (en) 2014-12-17
TW201336527A (zh) 2013-09-16
BR112014019742A2 (es) 2017-06-20
AU2013216847A1 (en) 2014-09-04
CN104168885A (zh) 2014-11-26
CA2864165A1 (en) 2013-08-15
JP6180443B2 (ja) 2017-08-16
WO2013119974A1 (en) 2013-08-15
US20140364422A1 (en) 2014-12-11
JP2015509933A (ja) 2015-04-02
MX2014009573A (es) 2015-04-08
KR102047954B1 (ko) 2019-11-22
AU2013216847B2 (en) 2016-06-23
EP2811979B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
SA518391268B1 (ar) Cftr مركبات وتركيبات وطرق لتعديل
SA517381828B1 (ar) Cftr مركبات، وتركيبات، وطرق لزيادة نشاط
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2015013774A (es) Administracion nasal.
ECSP13012384A (es) Composición acuosa que contiene bromhexina
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX354137B (es) Composiciones topicas de minociclina y metodos de uso de la misma.
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
TR201909447T4 (tr) Aramkol tuzları.
PH12015502382A1 (en) Pertuzumab variants and evaluation thereof
IN2015KN00005A (es)
AU342909S (en) Air freshener
MX2016005395A (es) Formulacion estable de insulina glulisina.
PH12014502571A1 (en) Ophthalmic compositions with improved dessication protection and retention
AU348086S (en) Air freshener refill
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX358132B (es) Solucion de trombina y metodos de uso de esta.
IN2014KN02745A (es)
AR090725A1 (es) Metodos para producir clorhidrato de anamorelina que tiene contenido controlado de cloruro
AU351587S (en) Respirator cartridge
MX365285B (es) Complejo lubricante para la boca.
MX2016005720A (es) Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto.
MX356050B (es) Composicion farmaceutica acuosa con estabilidad mejorada.

Legal Events

Date Code Title Description
FG Grant or registration